{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:04:00Z","timestamp":1774566240478,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2002,3,1]],"date-time":"2002-03-01T00:00:00Z","timestamp":1014940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2002,3]]},"DOI":"10.1006\/gyno.2001.6546","type":"journal-article","created":{"date-parts":[[2002,10,6]],"date-time":"2002-10-06T19:02:41Z","timestamp":1033930961000},"page":"420-425","source":"Crossref","is-referenced-by-count":57,"title":["A Comparison of Two Prophylactic Regimens for Hypersensitivity Reactions to Paclitaxel"],"prefix":"10.1006","volume":"84","author":[{"given":"Janice S.","family":"Kwon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie","family":"Elit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Finn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Hirte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Mazurka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francois","family":"Moens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Trim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1006\/gyno.2001.6546_RF1","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJM199504133321507","article-title":"Paclitaxel (Taxol)","volume":"332","author":"Rowinsky","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1006\/gyno.2001.6546_RF2","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.1990.8.7.1263","article-title":"Hypersensitivity reactions from Taxol","volume":"8","author":"Weiss","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6546_RF3","first-page":"605","article-title":"Phase I trial of Taxol given as a 3-hour infusion every 21 days","volume":"70","author":"Kris","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"10.1006\/gyno.2001.6546_RF4","first-page":"2486","article-title":"Phase I clinical and pharmacokinetic study of Taxol","volume":"47","author":"Wiernik","year":"1987","journal-title":"Cancer Res"},{"key":"10.1006\/gyno.2001.6546_RF5","first-page":"1171","article-title":"Phase I trial of Taxol in patients with advanced cancer","volume":"71","author":"Donehower","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"10.1006\/gyno.2001.6546_RF6","first-page":"1179","article-title":"Phase I study of Taxol administered as a short IV infusion daily for 5 days","volume":"71","author":"Grem","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"10.1006\/gyno.2001.6546_RF7","first-page":"82","article-title":"A phase I pharmacokinetic study of Taxol given by a prolonged infusion without premedication","volume":"8","author":"Koeller","year":"1989","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2001.6546_RF8","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.1994.12.12.2654","article-title":"European\u2013Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion","volume":"12","author":"Eisenhauer","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6546_RF9","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1023\/A:1008207025430","article-title":"Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions","volume":"8","author":"Bookman","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1006\/gyno.2001.6546_RF10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1006\/gyno.1997.4906","article-title":"Taxol hypersensitivity: rapid retreatment is safe and cost effective","volume":"68","author":"Olson","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1006\/gyno.2001.6546_RF11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1006\/gyno.2001.6546_RF12","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1200\/JCO.1996.14.6.1895","article-title":"Carboplatin and paclitaxel in ovarian carcinoma. A phase I study of the Gynecologic Oncology Group","volume":"14","author":"Bookman","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6546_RF13","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1200\/JCO.1997.15.12.3517","article-title":"Simplified regimen for the prevention of paclitaxel-associated hypersensitivity reactions","volume":"15","author":"Markman","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6546_RF14","unstructured":"National Cancer Institute of Canada\u2013Clinical Trials Group, Chemotherapy toxicity scale, 1994."},{"key":"10.1006\/gyno.2001.6546_RF15","series-title":"An introduction to categorical data analysis","author":"Agresti","year":"1996"},{"key":"10.1006\/gyno.2001.6546_RF16","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s004320050297","article-title":"An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions","volume":"125","author":"Markman","year":"1999","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1006\/gyno.2001.6546_RF17","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2000.18.1.102","article-title":"Paclitaxel-associated hypersensitivity reactions: experience of the Gynecologic Oncology Program of the Cleveland Clinic Cancer Centre","volume":"18","author":"Markman","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2001.6546_RF18","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1200\/JCO.1993.11.5.885","article-title":"Successful re-treatment with Taxol after major hypersensitivity reactions","volume":"11","author":"Peereboom","year":"1993","journal-title":"J Clin Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825801965461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825801965461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T15:21:41Z","timestamp":1554996101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825801965461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,3]]}},"alternative-id":["S0090825801965461"],"URL":"https:\/\/doi.org\/10.1006\/gyno.2001.6546","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2002,3]]}}}